Wednesday, May 13, 2026 An EN7 poster presentation at the United States & Canadian Academy of Pathology (USCAP) Conference, held 21-26 March, 2026 in San Antonio, TX. The abstract has been published in the journal Laboratory Investigation. A small but clinically relevant subset of endometrial carcinomas (EC) have more than one molecular classifying feature. Using the largest collection of molecularly classified EC-cohorts to date, researchers evaluated whether aberrant p53 status affects outcomes. Vermij L, Huvila J, Jamieson A, McAlpine J, Lueng S, Jobsen J, Smit V, de Boer S, Nout R, Powell M, Shepherd L, Kuijsters N, Haverkort M, de Jong M, Razack R, Butt J, de Kroon C, Creutzberg C, Bosse T, Gilks CB, Horeweg N. 1072 Large-scale Validation Confirms Lack of Prognostic Impact of Aberrant p53 Status in POLEmut and MMRd Endometrial Carcinoma. United States & Canada Academy of Pathology (USCAP) Conference. Laboratory Investigation 106 [3], 105362. 2026. https://doi.org/10.1016/j.labinv.2025.105362
